Document is current
Any future updates will be listed below
-
Authors
Novy, Brandon https://orcid.org/0000-0001-5304-2640
Dagunts, Aleksandra https://orcid.org/0000-0001-9378-8017
Weishaar, Tatum
Holland, Emily E.
Adoff, Hayden https://orcid.org/0000-0002-0373-3678
Hutchinson, Emily
De Maria, Monica
Kampmann, Martin https://orcid.org/0000-0002-3819-7019
Tsvetanova, Nikoleta G. https://orcid.org/0000-0001-6533-187X
Lobingier, Braden T. https://orcid.org/0000-0001-7881-7502
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM137835)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA043607)
Oregon Health and Science University
U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG062359)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS127847)
- License Information
-
More Information
Article History
Received: 15 August 2023
Accepted: 17 July 2024
First Online: 2 September 2024
Competing interests
: M.K. is a co-scientific founder of Montara Therapeutics, serves on the scientific advisory boards of Engine Biosciences, Casma Therapeutics, Cajal Neuroscience, Alector and Montara Therapeutics and is an advisor to Modulo Bio and Recursion Therapeutics. M.K. is an inventor on US patent 11,254,933 related to CRISPRi and CRISPRa screening and on a US patent application on in vivo screening methods. The other authors declare no competing interests.
